8. STOCK OPTIONS AND OTHER EQUITY AWARDS

The following table summarizes stock option activity during the six months ended March 31, 2015:

	Number of Options			Weighted- Average Exercise Price
Options outstanding and exercisable at September 30, 2014		32,500		$	14.22
Exercised		(600	)		14.22

Options outstanding and exercisable at March 31, 2015		31,900			14.22

All stock options outstanding at March 31, 2015 expire on September 30, 2015.

No options to purchase shares of common stock for the three and six months ended March 31, 2015 and 2014 were excluded from the computation of diluted earnings per share because none of the stock options were anti-dilutive.

During the six months ended March 31, 2015, the Company received proceeds of $9 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $1 and optionees realized an aggregate pre-tax gain of $3 from these stock option exercises. During the six months ended March 31, 2014, the Company received proceeds of $115 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $51 and optionees realized an aggregate pre-tax gain of $133 from these stock option exercises.

On January 28, 2013, stockholders approved the Nutraceutical International Corporation 2013 Long-Term Equity Incentive Plan (the "2013 Plan") and the reservation of 800,000 shares of the Company's common stock for issuance under the 2013 Plan. Equity awards available under the 2013 Plan include stock options, stock appreciation rights and stock awards. In conjunction with the Company's fiscal 2014 and fiscal 2013 incentive compensation (bonus) payments, 24,827 and 31,788 shares of the Company's common stock were issued, respectively. These non-cash stock awards were granted on December 11, 2014 and December 11, 2013 at an aggregate fair value of $504 and $775, respectively, with fair value being determined by the closing price of the Company's common stock on the grant date. These stock awards were registered, unrestricted and fully vested on the grant date. As of March 31, 2015, 743,385 shares of the Company's common stock were available for issuance under the 2013 Plan.